Navigation Links
Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
Date:12/8/2008

ches to the obesity epidemic," said Jack Lief, Arena's President and Chief Executive Officer. "We are confident the three ongoing lorcaserin Phase 3 trials will build on the clinical data published today, and we eagerly anticipate the announcement of our first Phase 3 data from the BLOOM trial around the end of March 2009. We expect the top-line BLOOM data will be followed by a peer reviewed presentation of the data at a conference later in the year, the announcement of BLOSSOM data in the Fall, and the submission of our New Drug Application to the FDA by the end of 2009."

A summary of results from this study were presented previously at the 2006 American Diabetes Association Scientific Sessions.

Study Design

The Phase 2b clinical trial evaluated the efficacy and safety of three doses of lorcaserin over a 12-week period in non-diabetic, obese patients. The trial was a randomized, double-blind, placebo-controlled study conducted at approximately 40 sites in the United States. The trial enrolled 469 men and women with a Body Mass Index (BMI) ranging from 30 to 45. Patients were randomized into four groups, receiving 10 mg once daily, 15 mg once daily, or 10 mg twice daily of lorcaserin, or placebo. The primary efficacy endpoint was a reduction in weight from baseline at the end of 12 weeks. There was no run-in period, and patients were counseled to maintain their usual diet and physical activity. Patients received echocardiograms at screening and the completion of the study (day 85).

Study Results

Patients completing 12 weeks of treatment with lorcaserin achieved progressive, dose-dependent and highly statistically significant weight loss of 4 pounds (1.8 kg), 5.7 pounds (2.6 kg) and 7.9 pounds (3.6 kg) at daily doses of 10 mg, 15 mg and 20 mg (10 mg twice daily), respectively, compared to weight loss of 0.7 pounds (0.3 kg) for placebo (p<0.001 for each group). Similar res
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference
2. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
3. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
4. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
5. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
6. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
8. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
11. Arena Pharmaceuticals Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 Quincy Bioscience, a fast-growing ... health supplement Prevagen®, releases the second edition of the ... for Making Memories: Birth of a Grandchild. , ... exceptional memory-making tips and ideas for grandparents to utilize ... a grandchild. Each concept published in the e-book is ...
(Date:7/31/2014)... FL. (PRWEB) July 31, 2014 ... USARAD Holdings Inc. a leading US Joint Commission ... the most innovative and technologically advanced consumer storage ... The teleradiology leader is providing valued members the ... enhancing the extraordinary services already offered by SecondOpinions.com®. ...
(Date:7/31/2014)... During an annual summer didactic and live ... Dallas plastic surgeon and a member of the ... demonstration of facial anatomy and key advances in facial ... Summer Meeting of the Cosmetic Bootcamp included lectures, anatomical ... key principles in modern facial surgery. , One of ...
(Date:7/31/2014)... July 31, 2014 Body Well Therapy ... insurance patients seeking massage therapy in all 44 states ... option for Licensed Massage Therapists who do not otherwise ... to BWT. Should a patient request a specific qualified ... can then contract the therapist to provide therapeutic massage ...
(Date:7/31/2014)... 2014 Cheerag D. Upadhyaya ... neurosurgeons at the Saint Luke’s Marion Bloch Neuroscience ... director of spine surgery. He comes to SLMBNI from ... Upadhyaya has been recognized for his excellent work, research ... His addition to the Saint Luke’s Marion Bloch Neuroscience ...
Breaking Medicine News(10 mins):Health News:Quincy Bioscience Launches the Second E-Book of the Making Memories Series 2Health News:SECONDOPINIONS.COM® Introduces Innovative Cloud-Based Medical Imaging Exchange Service for Easy Upload, Access and Sharing Anytime/Anywhere 2Health News:SECONDOPINIONS.COM® Introduces Innovative Cloud-Based Medical Imaging Exchange Service for Easy Upload, Access and Sharing Anytime/Anywhere 3Health News:Dr. Rod J. Rohrich Demonstrates Advances in Facial Surgery at Annual Cosmetic Surgery Seminar 2Health News:Dr. Rod J. Rohrich Demonstrates Advances in Facial Surgery at Annual Cosmetic Surgery Seminar 3Health News:Body Well Therapy Invites Massage Therapists Nationwide to "Bring Your Own Insurance Clients" 2Health News:Body Well Therapy Invites Massage Therapists Nationwide to "Bring Your Own Insurance Clients" 3Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 2Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 3Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 4
... ... top of the world and sharing her story of hope and determination. , ... Bayfield, WI (PRWEB) April 7, 2010 -- Hopeful climbers have ... to climb the world,s highest peak. Last year,s successful climbers whose summit of Everest ...
... ... to Win an Appearance on National Television—or Win an Apple iPad™ in the “Best Seller ... ... lead to TODAY’S publishing of Gerry Czarnecki’s latest book… Lead with Love. This is ...
... researchers of over eight years of dietary data from more ... consumption of fruits and vegetables and a reduced risk of ... is published online April 6, 2010 in the Journal ... believed that a diet rich in fruits and vegetables can ...
... at initial screening often didn,t have recommended colonoscopy, study ... Americans are less likely than whites to have a ... sigmoidoscopy screening test, says a new study. , ... risk for colorectal cancer and more likely to die ...
... say , TUESDAY, April 6 (HealthDay News) -- The use ... in the past six years, even though these operations ... necessarily more effective, a study finds. , "It was a ... was," said Dr. Richard A. Deyo, professor of family medicine ...
... previously used exclusively by academic researchers has successfully been ... national strategies to curtail the spread of HIV, meaning ... , A new study by researchers at the University ... would work when led by CBOs, who have played ...
Cached Medicine News:Health News:Woman with MS Summits Everest and Completes the Seven Summits 2Health News:Woman with MS Summits Everest and Completes the Seven Summits 3Health News:&#8216;Leading' the Bestseller Race: Today We Publish &#8212;Tomorrow We Prevail! 2Health News:&#8216;Leading' the Bestseller Race: Today We Publish &#8212;Tomorrow We Prevail! 3Health News:Mount Sinai study finds only a weak link between fruit and vegetable and reduced risk of cancer 2Health News:Blacks Less Likely to Get Follow-Up Colon Screening 2Health News:Complex Spinal Operations Soar Despite Drawbacks 2Health News:Complex Spinal Operations Soar Despite Drawbacks 3Health News:Roll-out of proven HIV/STD risk-reduction intervention with teens by community groups successful 2
(Date:7/31/2014)... De Pfizer Clinical Research Unit (PCRU) heeft ... van Japanse komaf voor medewerking aan klinisch onderzoek. De ... één van twee onderzoekseenheden van Pfizer , een ... door de ontdekking en ontwikkeling van nieuwe medicijnen. Om ... mannen en vrouwen van Japanse komaf – leeftijd 18 ...
(Date:7/30/2014)... , July 30, 2014  Cepheid (Nasdaq: ... group purchasing contract with Premier will end on ... Premier GPO will be able to continue their ... Baycare, HPA, MedAssets, Novation, and ROi, in addition ... directly with Cepheid. "Cepheid has always ...
(Date:7/30/2014)... 2014 The Board of Directors of ... evening expressed support for the "Pharmacists, Patient Care ... Pharmacy Practitioners (JCPP).  As a JCPP member, AMCP ... period to develop a scalable, viable and consistent ... "Pharmacists are fast becoming one of the most ...
Breaking Medicine Technology:Gezonde vrijwilligers van Japanse komaf gezocht voor deelname aan Fase I klinisch onderzoek 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3AMCP Endorses JCPP "Pharmacists' Patient Care Process" 2
... Reportlinker.com announces that a new market ... Commercial Insight: Antihormonal Cancer ... generic sales erosion ... therapies are a class of drugs used ...
... NEW YORK, Nov. 8, 2010 Reportlinker.com ... is available in its catalogue: ... for optimizing growth in key regions and ... The flurry of recent ...
Cached Medicine Technology:Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 2Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 3Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 4Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 5Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 6Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 7Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 8Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 9Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 2Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 3Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 4Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 5Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 6Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 7
... As a prophylaxis for deep vein ... effective combination of graduated sequential compression and ... thrombus formation by increasing venous ejection while ... VenaFlow System includes a pump with tube ...
... Full Transportability: Innovative design allows the ... in for therapy or when to ... Choose the prophylactic method to deliver ... both simultaneously. ,Automatic Garment Detection: Automatically ...
... boot specially lasted for fiberglass casts... ... sole for easy ambulation! ,The SlimLine ... last so it fits better than ... with our stretchable upper, a custom ...
The Low Profile boot provides a durable canvas upper, with an open toe and heel. Padded EVA insole protection. The lower outsole compensates for casting thickness. Available in six unisex sizes....
Medicine Products: